Aura Biosciences, Inc. Common Stock (AURA) Stock
Key stats
- Market cap
- $792.01M
- Price / Earnings ratio
- -5.8x
- EPS (TTM)
- -$1.64
- Volume
- Loading
- 52-week high
- $9.54
- 52-week low
- $4.73
Source: third-party data provider, as of November 13, 2026
Compare with AURA
Recent news

Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
AURA

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
AURA

Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
AURA

Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
AURA
Technical indicators
- RSI 14
- 67.82
- MACD 12/26/9
- 0.22
- EMA 9 of MACD
- 0.04
- MACD histogram
- 0.18
- SMA 50
- $6.56
- Price above SMA 50
- EMA 50
- $6.67
- Price above EMA 50
- SMA 200
- $6.77
- Price above SMA 200
- EMA 200
- $6.56
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
AURA

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
AURA

Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
AURA

Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
AURA
About Aura Biosciences, Inc. Common Stock
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Natalie C. Holles | President, CEO & Director | 1973 |
| Ms. Susan Abu-Absi Ph.D. | Chief Operating Officer | — |
| Dr. J. Jill Hopkins M.D. | Chief Medical Officer & President of Research and Development | 1965 |
| Ms. Amy Elazzouzi | Senior Vice President of Finance, Treasurer and Secretary | 1974 |
| Alex Dasalla | Head of Investor Relations & Corporate Communications | — |
| Ms. Julie Person | Chief People Officer | 1974 |
| Mr. Patrick Nealon | Senior Vice President of Clinical Development Operations | — |
| Dr. Anthony Daniels M.D. | VP & Therapeutic Area of Head Ocular Oncology | — |
| Ms. Erica Kratz Ph.D. | Chief Regulatory & Quality Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 67.82
- MACD 12/26/9
- 0.22
- EMA 9 of MACD
- 0.04
- MACD histogram
- 0.18
- SMA 50
- $6.56
- Price above SMA 50
- EMA 50
- $6.67
- Price above EMA 50
- SMA 200
- $6.77
- Price above SMA 200
- EMA 200
- $6.56
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +6.6 | -1.3 | +4.2 | +2.0 | -15.5 | +1.7 | +26.9 |



